EUVIMEDObjevte EUVIMED
Crossref

Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs

Agustin Pappolla, Cristina Auger, Augusto Sao-Aviles, Carmen Tur iD, Marta Rodriguez-Barranco, Álvaro Cobo-Calvo iD, Neus Mongay-Ochoa, Breogán Rodríguez-Acevedo iD, Ana Zabalza iD, Luciana Midaglia, Pere Carbonell-Mirabent, Rene Carvajal iD and 14 more

Multiple Sclerosis Journal · 2024

DOI: 10.1177/13524585241240653 ↗

At a glance

Journal article in Multiple Sclerosis Journal, 2024. Written by Agustin Pappolla and 25 co-authors. Institution: Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital U…. Major MEDLINE topics: Multiple Sclerosis, Relapsing-Remitting, Treatment Failure. Cited 2 times so far (Crossref); 34 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Limited data exist regarding treatment response prediction to oral disease-modifying therapies (DMTs) in multiple sclerosis (MS).

Objectives

We assessed the capacity of available scoring systems to anticipate disease activity parameters in naïve relapsing–remitting MS (RRMS) patients initiating daily oral DMTs, hypothesizing that they exhibit different predictive potentials.

Methods

We conducted a retrospective study and applied the Rio Score (RS), modified Rio Score (mRS), and MAGNIMS Score 12 months after DMT initiation. At 36 months, we examined their ability to predict evidence of disease activity (EDA) components and treatment failure by logistic regression analysis.

Results

Notably, 218 patients (62.4% females) initiating dimethyl fumarate, teriflunomide, and fingolimod were included. At 36 months, the RS high-risk group predicted evidence of clinical activity (odds ratio (OR) 10 [2.7–36.9]) and treatment failure (OR 10.6 [3.4–32.5]) but did not predict radiological activity (OR 1.9 [0.7–5]). The mRS non-responders group did not predict EDA and treatment failure. RS, mRS, and MAGNIMS 0 categories showed significantly lower EDA and treatment failure than the remainder.

Conclusion

Scoring systems present different predictive abilities for disease activity parameters at 36 months in MS patients initiating daily oral therapies, warranting further adjustments (i.e. introduction of fluid biomarkers) to depict disease activity status fully.

Subjects

MeSH terms (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingTreatment FailureHumansFemaleAdultMaleRetrospective StudiesAdministration, OralMiddle AgedFingolimod HydrochlorideDimethyl FumarateCrotonatesHydroxybutyratesToluidinesImmunosuppressive AgentsNitrilesPrognosisImmunologic Factors

Author keywords

Treatment responsedisease-modifying therapiesevidence of disease activitynon-evidence of disease activitytreatment failure

Substances

teriflunomideFingolimod HydrochlorideDimethyl FumarateCrotonatesHydroxybutyratesToluidinesImmunosuppressive AgentsNitrilesImmunologic Factors

Authors and institutions

  • Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Section of Neuroradiology, Department of Radiology, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Statistics and Bioinformatics Unit, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Barcelona, Spain.

ORCID profiles: Carmen Tur, Álvaro Cobo-Calvo, Breogán Rodríguez-Acevedo, Ana Zabalza, Rene Carvajal, Angela Vidal-Jordana, Georgina Arrambide, Jaume Sastre-Garriga, Mar Tintoré, Alex Rovira, Jordi Río

Cite

APA

Pappolla, A., Auger, C., Sao-Aviles, A., Tur, C., Rodriguez-Barranco, M., Cobo-Calvo, Á., Mongay-Ochoa, N., Rodríguez-Acevedo, B., Zabalza, A., Midaglia, L., Carbonell-Mirabent, P., Carvajal, R., Castilló-Justribó, J., Braga, N., Bollo, L., Vidal-Jordana, A., Arrambide, G., Nos, C., Salerno, A., …, & Río, J. (2024). Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241240653

Vancouver

Pappolla A, Auger C, Sao-Aviles A, Tur C, Rodriguez-Barranco M, Cobo-Calvo Á, et al. Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241240653

BibTeX
@article{Pappolla2024,
  author = {Pappolla, Agustin and Auger, Cristina and Sao-Aviles, Augusto and Tur, Carmen and Rodriguez-Barranco, Marta and Cobo-Calvo, Álvaro and Mongay-Ochoa, Neus and Rodríguez-Acevedo, Breogán and Zabalza, Ana and Midaglia, Luciana and Carbonell-Mirabent, Pere and Carvajal, Rene and Castilló-Justribó, Joaquín and Braga, Nathane and Bollo, Luca and Vidal-Jordana, Angela and Arrambide, Georgina and Nos, Carlos and Salerno, Annalaura and Galán, Ingrid and Comabella, Manuel and Sastre-Garriga, Jaume and Tintoré, Mar and Rovira, Alex and Montalban, Xavier and Río, Jordi},
  title = {Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs},
  journal = {Multiple Sclerosis Journal},
  year = {2024},
  doi = {10.1177/13524585241240653}
}
Start for free →